DoD’s BioDefense Therapeutics Announces Positive Results for Flu Treatment Drug

The successful completion of a Phase 2 double blind placebo-controlled clinical trial for the anti-influenza drug, T-705a (favipiravir), clears the way for Phase 3 clinical trials to begin in November. The investigational drug candidate is being developed by BioDefense Therapeutics (BD Tx)—a Joint Product Management office within the U.S. Department of Defense (DoD)—through a contract with Boston-based MediVector, Inc.

Read More.